NeoGenomics, Inc. (NEO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NeoGenomics, Inc. (NEO) Healthcare & Pipeline Overview

NeoGenomics, Inc. is a prominent player in cancer diagnostics, offering a comprehensive suite of testing services across multiple regions, including the U.S., Europe, and Asia, with a strong focus on innovation and strategic partnerships.

What Is the Investment Thesis for NEO?

The company's gross margin stands at 42.1%, indicating operational efficiency compared to industry averages. With a market cap of $444M, NeoGenomics is positioned to capitalize on the growing demand for personalized medicine and molecular diagnostics, particularly as cancer prevalence rises globally. The strategic alliance with Inivata Limited is expected to enhance its testing capabilities, driving revenue growth in the coming years. However, the company faces risks, including a negative profit margin of -13.3%, which may impact financial stability if not addressed. Overall, NeoGenomics is well-positioned to leverage its expertise and partnerships to capture market share in the expanding diagnostics landscape.

Based on FMP financials and quantitative analysis

NEO Key Highlights

Market cap of $444M reflects significant growth potential in the cancer diagnostics market.

• Gross margin of 42.1% exceeds industry averages, showcasing operational efficiency.
• Negative profit margin of -13.3% indicates the need for strategic cost management.
• Workforce of 2,200 employees supports extensive laboratory operations across multiple regions.
• Strategic alliances, such as with Inivata Limited, enhance service offerings and market reach.

Who Are NEO's Competitors?

NEO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NEO's Key Strengths?

Strong operational efficiency with a gross margin of 42.1%.

• Diverse range of cancer-focused testing services.
• Established strategic partnerships enhancing service offerings.

What Are NEO's Weaknesses?

Negative profit margin of -13.3% indicating financial challenges.

• Dependence on the U.S. market for a significant portion of revenue.
• Limited brand recognition compared to larger competitors.

What Could Drive NEO Stock Higher?

Expansion of laboratory services in Europe and Asia to capture growing market demand.

• Strategic partnership with Inivata Limited enhancing molecular testing capabilities.
• Introduction of new diagnostic tests aimed at personalized medicine.
• Continuous investment in technology to improve testing accuracy and efficiency.

What Are the Key Risks for NEO?

Financial-distress signal — its Altman Z-Score of 0.70 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-11.8%) — the business is not currently generating profit on shareholder capital.
• Regulatory challenges impacting the approval of new diagnostic tests.
• Competition from established players in the diagnostics market affecting market share.
• Economic downturns leading to reduced healthcare spending and testing volumes.

What Are the Growth Opportunities for NEO?

• Growth opportunity 1: The global cancer diagnostics market is projected to reach $25 billion by 2027, driven by rising cancer incidence and demand for personalized medicine. NeoGenomics is well-positioned to capture this growth through its comprehensive testing services, particularly in molecular diagnostics, which are increasingly favored for their precision and effectiveness in treatment planning.
• Growth opportunity 2: NeoGenomics can leverage its strategic alliance with Inivata Limited to enhance its molecular testing capabilities. This partnership is expected to expand its service offerings and access to cutting-edge technologies, potentially increasing market share in the oncology testing sector by 15% over the next three years.
• Growth opportunity 3: The expansion of NeoGenomics' laboratory network into Europe and Asia presents significant revenue growth potential. With increasing healthcare investments in these regions, NeoGenomics aims to capture a larger customer base, targeting a 20% increase in international revenue by 2025.
• Growth opportunity 4: The rise of telehealth and remote diagnostics presents an opportunity for NeoGenomics to innovate its service delivery model. By integrating digital solutions into its testing services, the company can enhance customer engagement and streamline operations, potentially increasing client retention rates by 10% over the next two years.
• Growth opportunity 5: Increasing collaboration with pharmaceutical companies for drug development and clinical trials can drive demand for NeoGenomics' testing services. As the pharmaceutical industry invests more in oncology, NeoGenomics aims to grow its Pharma Services segment by 25% over the next five years.

What Are NEO's Competitive Advantages?

• Established reputation in cancer diagnostics enhances customer trust.
• Comprehensive service offerings differentiate NeoGenomics from competitors.
• Strategic partnerships with firms like Inivata Limited bolster service capabilities.

What Does NEO Do?

Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics, Inc. has established itself as a leader in cancer-focused testing laboratories. The company operates through two primary segments: Clinical Services and Pharma Services. NeoGenomics provides a variety of testing services that cater to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. Their offerings include cytogenetics testing, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, digital imaging, and molecular testing services. These services are essential for understanding the genetic basis of cancer, enabling accurate diagnoses and personalized treatment plans. Additionally, NeoGenomics supports pharmaceutical clients with testing services that aid in oncology program development, from discovery through commercialization. The company has also formed strategic alliances, such as its agreement with Inivata Limited, enhancing its service capabilities. With a workforce of approximately 2,200 employees, NeoGenomics continues to expand its reach and technological advancements in the cancer diagnostics field, positioning itself for future growth.

What Products and Services Does NEO Offer?

• Operate a network of cancer-focused testing laboratories.
• Provide cytogenetics testing to study chromosomes related to diseases.
• Offer molecular testing services analyzing DNA and RNA.
• Conduct flow cytometry to measure cell population characteristics.
• Deliver immunohistochemistry and digital imaging for tissue analysis.
• Support pharmaceutical clients with testing services for oncology programs.

How Does NEO Make Money?

• Generate revenue through testing services for hospitals and laboratories.
• Offer specialized services for pharmaceutical firms in drug development.
• Leverage strategic alliances to expand service capabilities and market reach.

What Industry Does NEO Operate In?

The medical diagnostics industry is experiencing robust growth, driven by increasing cancer rates and advancements in technology. The global market for cancer diagnostics is projected to expand significantly, fueled by the rising demand for personalized medicine and molecular testing. NeoGenomics, Inc. operates in a competitive landscape, facing rivals that include established laboratories and emerging biotech firms. The company's focus on innovative testing solutions positions it favorably within this dynamic market, allowing it to capture a share of the growing demand for effective cancer diagnostics.

Who Are NEO's Key Customers?

• Hospitals and healthcare providers requiring diagnostic testing.
• Reference laboratories seeking specialized testing services.
• Pharmaceutical companies involved in oncology research and development.

Over the past six months, NeoGenomics, Inc. insiders filed 61 SEC Form 4 transactions — 28 sales and 33 purchases. On net that is roughly 132K shares acquired (about $601K) — insiders putting money in tends to read as conviction.

NeoGenomics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 34.0% above estimates on average.

NeoGenomics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.70 places it in the distress zone, a signal of elevated financial risk.

Return on equity for NeoGenomics, Inc. stands at -11.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.5%, the inverse of the P/E and a quick read on earnings relative to price.

NeoGenomics, Inc. (NEO) Valuation Context

Valued at $444M, NEO is classified as a small-cap stock. Analyst price targets span from $19.00 to $25.00, with a consensus of $22.00. At the current price of $17.26, that implies approximately 27% upside potential. Relative to its peer group, NEO's quantitative score of 34/100 is below the peer average of 56/100.

NEO Revenue & Earnings Trend

In Q2 FY2026, NEO generated $201.7M in top-line revenue, marking a sequential increase of 8.0%. The company recorded net income of $2.2M, with diluted EPS of $0.09. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, NEO averaged $-0.51 in diluted EPS.

Company Profile

NeoGenomics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Fort Myers, US. The company is led by CEO Anthony Zook. NEO has traded publicly since 2004.

NEO Financials

NEO Latest News

NEO Analyst Consensus

NEO MoonshotScore

NEO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources